FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
